Core Laboratories Inc. CLB
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 516.74M | 519.18M | 524.73M | 526.52M | 517.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 516.74M | 519.18M | 524.73M | 526.52M | 517.50M |
| Cost of Revenue | 418.05M | 417.86M | 420.19M | 417.59M | 414.27M |
| Gross Profit | 98.69M | 101.32M | 104.54M | 108.93M | 103.23M |
| SG&A Expenses | 46.22M | 45.67M | 45.23M | 44.23M | 42.70M |
| Depreciation & Amortization | 14.98M | 14.85M | 14.70M | 14.65M | 14.65M |
| Other Operating Expenses | -1.28M | -1.48M | -1.26M | -1.66M | -1.53M |
| Total Operating Expenses | 477.98M | 476.90M | 478.86M | 474.80M | 470.09M |
| Operating Income | 38.76M | 42.28M | 45.88M | 51.72M | 47.41M |
| Income Before Tax | 27.80M | 36.80M | 43.08M | 45.90M | 44.22M |
| Income Tax Expenses | 12.17M | 12.10M | 13.51M | 15.51M | 11.49M |
| Earnings from Continuing Operations | 15.64 | 24.70 | 29.57 | 30.39 | 32.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -78.00K | -344.00K | -535.00K | -722.00K | -607.00K |
| Net Income | 15.56M | 24.35M | 29.03M | 29.67M | 32.12M |
| EBIT | 38.76M | 42.28M | 45.88M | 51.72M | 47.41M |
| EBITDA | 53.74M | 57.13M | 60.57M | 66.37M | 62.06M |
| EPS Basic | 0.34 | 0.53 | 0.62 | 0.64 | 0.69 |
| Normalized Basic EPS | 0.35 | 0.39 | 0.44 | 0.52 | 0.45 |
| EPS Diluted | 0.33 | 0.52 | 0.61 | 0.62 | 0.67 |
| Normalized Diluted EPS | 0.34 | 0.39 | 0.43 | 0.51 | 0.45 |
| Average Basic Shares Outstanding | 184.67M | 185.06M | 185.67M | 186.37M | 187.44M |
| Average Diluted Shares Outstanding | 186.36M | 186.73M | 187.21M | 187.91M | 188.99M |
| Dividend Per Share | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Payout Ratio | 11.86% | 7.60% | 6.41% | 6.30% | 5.83% |